Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.

@article{Cattaneo2010TanezumabAR,
  title={Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.},
  author={Antonino Cattaneo},
  journal={Current opinion in molecular therapeutics},
  year={2010},
  volume={12 1},
  pages={94-106}
}
Persistent pain represents a major health problem, and most current therapeutic approaches are associated with unwanted effects and unsatisfactory pain relief. Therefore, an urgent need exists to develop more effective drugs that are directed toward new molecular targets. Nerve growth factor (NGF) is involved in pain transduction mechanisms, playing a key role as a master switch in many chronic and inflammatory pain states; the NGF ligand and its receptor TrkA constitute well-validated targets… CONTINUE READING